April 10, 2025, Paper: "The second Trump Administration is moving forward at an extraordinary pace. Widespread efforts to reduce government…
Medicare Part D does not allow plans to exclude drugs in six protected classes from their formularies, which may limit plans’ ability to…
The Resilient Society by Markus Brunnermeier is a creative, wide-ranging book that aims and often succeeds at providing a new perspective…
The Inflation Reduction Act (IRA) of 2022 is the most significant reform to US prescription drug pricing in two decades and the first…
There are widespread differences in total factor productivity across producers in the U.S. and around the world. To help explain these…
The United States spends substantially more on health care than most developed countries, yet leaves a greater share of the population…
Background
The COVID-19 pandemic has adversely impacted child development and the well-being of caregivers, and such evidence ought to be…
Medicare Part D is an outpatient prescription drug benefit for older Americans covering more than 46 million beneficiaries. Except for…
January 2022. GrowthPolicy’s Devjani Roy interviewed Joseph Fuller, Professor of Management Practice at Harvard Business School and Faculty…
June 25, 2020, Paper, "Governors and other policymakers can avoid a second wave of COVID-19 deaths, or turn it around if it starts, by re-…